66
Participants
Start Date
November 30, 2004
Primary Completion Date
March 31, 2009
Study Completion Date
August 31, 2009
131-I-TM-601
131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
131I-TM601
131I-TM601, in solution, delivered intracavitarily following surgical resection 6 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
Columbia University Medical Center, New York
Johns Hopkins Medical Center, Baltimore
Carolina Neurosurgery and Spine, Charlotte
Emory University, Atlanta
Florida Hospital Cancer Institute, Orlando
Moffitt Cancer Center, Tampa
Henry Ford Hospital, Detroit
Lacks Cancer Center at St. Mary's Health Care, Grand Rapids
Northwestern University, Chicago
University of Chicago, Chicago
St. Louis Hospital, St Louis
Washington University Medical Center, St Louis
Mary Crowley Medical Research Center, Dallas
Huntsman Cancer Institute, Salt Lake City
Cedars-Sinai Medical Center, Los Angeles
City of Hope, Duarte
University of Alabama at Birmingham, Birmingham
Tufts-New England Medical Center, Boston
University of Washington, Seattle
Lead Sponsor
TransMolecular
INDUSTRY